The better performance of plasma methylated DNA markers (MDMs) for HCC diagnosis (Kisiel et al. 2019) has been validated in a phase 2 study (n = 244, AUROC 0.96, sensitivity 95%, specificity 92%), which captures 6-marker changes (HOXA1, EMX1, AK055957, ECE1, PFKP, and CLEC11A normalized by B3GALT6). The gene discussed is HOXA1; the disease is hepatocellular carcinoma.